These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3498947)

  • 1. Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC).
    Sondel PM; Hank JA; Rosenthal N; Moore KH; Hong R; Storer B; Kohler PC
    Prog Clin Biol Res; 1987; 244():173-84. PubMed ID: 3498947
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo and in vitro activation of NK cytotoxicity with IL-2.
    Ibayashi Y; Tokuda Y; Saks ER; Sarna GP; Golub SH
    Prog Clin Biol Res; 1987; 244():275-85. PubMed ID: 3498954
    [No Abstract]   [Full Text] [Related]  

  • 3. Augmentation of NK cell activity by IL-2.
    Herberman RB
    Prog Clin Biol Res; 1987; 244():267-74. PubMed ID: 3498952
    [No Abstract]   [Full Text] [Related]  

  • 4. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells.
    Son YI; Dallal RM; Mailliard RB; Egawa S; Jonak ZL; Lotze MT
    Cancer Res; 2001 Feb; 61(3):884-8. PubMed ID: 11221875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of tumor-infiltrating lymphocytes from human solid tumors in interleukin-2.
    Whiteside TL; Heo DS; Chen K; Adler A; Johnson JT; Herberman RB
    Prog Clin Biol Res; 1987; 244():213-22. PubMed ID: 3309998
    [No Abstract]   [Full Text] [Related]  

  • 6. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2.
    Pope BL; Chourmouzis E; Victorino L; MacIntyre JP; Capetola RJ; Lau CY
    J Immunol; 1993 Sep; 151(6):3007-17. PubMed ID: 8376766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors.
    Grimm EA
    Prog Clin Biol Res; 1987; 244():185-95. PubMed ID: 3498948
    [No Abstract]   [Full Text] [Related]  

  • 9. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.
    Robertson MJ; Cameron C; Lazo S; Cochran KJ; Voss SD; Ritz J
    Nat Immun; 1996-1997; 15(5):213-26. PubMed ID: 9390270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
    Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
    Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
    Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
    Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.
    Cesano A; Visonneau S; Clark SC; Santoli D
    J Immunol; 1993 Sep; 151(6):2943-57. PubMed ID: 8104216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of interleukin-15 on the expression of killer-cell immunoglobulin-like receptors on peripheral natural killer cells in human.
    Kogure T; Mantani N; Goto H; Shimada Y; Tamura J; Terasawa K
    Mediators Inflamm; 2002 Aug; 11(4):219-24. PubMed ID: 12396473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive effect of cyclosporine and verapamil on the inhibition of activation and function of human peripheral blood mononuclear cells.
    Weir MR; Peppler R; Gomolka D; Handwerger BS
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):240-4. PubMed ID: 2966479
    [No Abstract]   [Full Text] [Related]  

  • 16. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of long-term cyclosporine therapy on natural killer cell activity.
    Versluis DJ; Metselaar HJ; Bijma AM; Vaessen LM; Wenting GJ; Weimar W
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):179-85. PubMed ID: 3129839
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential effect of interleukin 10 on interleukin 12- and interleukin 2-mediated killer induction from blood mononuclear cells.
    Pai K; Yanagawa H; Takauchi E; Suzuki Y; Hanibuchi M; Parajuli P; Sone S
    Oncol Res; 1998; 10(6):295-300. PubMed ID: 9848100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
    Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
    Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC 45662).
    Weir MR; Li XW; Gomolka D; Peppler R; O'Bryan-Tear G; Moran M
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1074-7. PubMed ID: 1989152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.